Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,866,304 shares, a decline of 9.1% from the November 15th total of 2,052,019 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily volume of 427,485 shares, the short-interest ratio is presently 4.4 days.
A number of equities analysts have commented on ATNM shares. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. B. Riley set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, Roth Capital reissued a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd.
Shares of Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.69 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/actinium-pharmaceuticals-inc-atnm-short-interest-update.html.
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.